[A case report of S-1 monotherapy responding to unresectable gallbladder cancer].
A 68-year-old man was found to have a gallbladder cancer. Curative operation was impossible because the gallbladder cancer invaded around the gallbladder in CT on 15th of April, 2008. S-1 monotherapy (120 mg/day) was started. S-1 was given orally twice daily for 4 weeks followed by 2 weeks without a treatment. There was no remarkable side effect. The gallbladder cancer was smaller in CT on 25th of September, 2008, and we confirmed a partial response (PR) in CT on 13th of February, 2009. In a pilot phase II study of S-1 for biliary tract cancer, the overall objective response rate was 35.0%. There was no severe side effect. S-1 is one of the effective drugs for biliary tract cancer.
Kirihara
Masato
M
Department of Surgery, Kawaguchi Kougyou General Hospital.
Nagashima
Michio
M
Ogura
Toshirou
T
Tahira
Hideaki
H
Tajima
Masayuki
M
D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005706:Gallbladder Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid